We are live on ! Find out more

Neumora Therapeutics

NMRA

Market cap $246M

1.31 USD

-0.04

2.96%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

1.31

0.00

0%

1 day

-2.96%

5 days

-6.43%

1 month

-18.13%

3 months

-25.14%

6 months

-57.05%

Year to date

-21.08%

1 year

-19.63%

5 years

-91.94%

10 years

-91.94%

About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Employees: 63

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 66.7%

Negative 33.3%

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who lost money on NMRA are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected].

NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW YORK, June 16, 2026 /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) shareholders lost significant value today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction.

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Zacks Investment Research

Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure

NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.

Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail

Neumora Therapeutics Inc. (NASDAQ:NMRA) on Monday said it is discontinuing development of its lead depression candidate, navacaprant, after two Phase 3 studies failed to achieve statistical significance on both primary and key secondary endpoints in patients with major depressive disorder (MDD).

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail

NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.

ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) complied with federal securities laws. On June 15, 2026, Neumora announced that “the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (MDD) did not achieve statistical significance on the primary or key secondary endpoints.

NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.

Neumora Therapeutics scraps depression drug after two late-stage trial failures

Neumora Therapeutics said on ‌Monday it would stop developing its depression drug after two late-stage trials failed ⁠to meet their main goals.

Neumora Therapeutics scraps depression drug after two late-stage trial failures

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease Aligning organization to support initiation of multiple clinical studies, with cash runway into the third quarter of 2027 WATERTOWN, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (MDD) did not achieve statistical significance on the primary or key secondary endpoints.

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m.

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

See News Rankings

Price charts implemented using Lightweight Charts™